Endometriosis Clinical Trial
— Physio-EndEAOfficial title:
'Physio-EndEA' Study: a Randomized Controlled Trial to Evaluate the Effect of a Supervised and Adapted Rehabilitation Program to Improve Quality of Life in Women Diagnosed With Endometriosis
Verified date | April 2022 |
Source | Universidad de Granada |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Given (1) the high volume of women on reproductive age that have a clinical diagnosis of endometriosis and (2) the poor management of symptoms that medical treatment usually achieves, new therapeutic interventions need to be evaluated in order to improve pain and quality of life in those patients. Therefore, 'Physio-EndEA' study has been designed to evaluate whether therapeutic exercise could help on the management of endometriosis-related symptoms
Status | Completed |
Enrollment | 26 |
Est. completion date | December 1, 2021 |
Est. primary completion date | December 1, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Premenopausal status - Clinical diagnosis of endometriosis by laparoscopy, magnetic resonance imaging or ultrasound imaging - History of clinical symptoms - To be able to walk without assistance - To be able to read and write enough - To be capable and willing to provide consent - Interested in improving lifestyle Exclusion Criteria: - Acute or terminal illness - Presence of any chronic disease or orthopedic issues that would interfere with ability to participate in a physical activity program - Unwillingness to complete the study requirements - Be registered in other exercise program |
Country | Name | City | State |
---|---|---|---|
Spain | Francisco Artacho Cordón | Granada |
Lead Sponsor | Collaborator |
---|---|
Universidad de Granada |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in quality of life assessed by EHP-30 | It will be assessed using the Endometriosis Health Profile-30 (EHP-30). It is a self-administered disease-specific instrument to measure QoL in women with endometriosis. The 30-item EHP, referred to the last 4 weeks, is comprised of five domains: pain, control and powerlessness, emotional well-being, social support, and self-image. Items within each subscale, answered on a 5-point Likert-type scale, are summed and then transformed to a percentage scale ranging from 0 (best health status) to 100 (worse health status) by dividing the raw score of all items by the maximum possible raw score, multiplied by 100 | Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Pressure pain threshold (PPT) | Algometry will be used to measure PPT levels in abdomen, pelvis and lower back regions through an electronic algometer. For this purpose, an approximate rate of 30 kilopascal/s will be applied with a 1cm2 probe. Seven points from the abdominal and pelvic area, and two additional points from the lower back region will be tested. Prior PPT assessment, assessor will ask for participants to press the switch when they first feel a change from pressure to pain. The mean of three tests, spaced by 30 s, will be used for the analysis. | Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Pain intensity | Visual Analogue Scale will be used to identify self-reported levels of chronic pelvic pain, dysmenorrhea, dyspareunia, dyschezia and dysuria.. Scores range from 0 to 10. Higher scores represent increased pain intensity | Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Catastrophizing thoughts | The Pain Catastrophizing Scale (PCS) will be also used to assess catastrophic thinking related to pain. Scores of this 13-item scale range from 0 to 52. Higher scores represent higher catastrophic thoughts. | Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Muscle thickness | Images of the abdominal wall, lumbar multifidus and quadriceps will be obtained using an ultrasound device with a 12 megahertz linear probe and a depth of 5 cm. The thicknesses of the external and internal oblique, the transversus abdominal muscles and the lumbar multifidus, as well as the width of the lumbar multifidus will be assessed. Three measurements of both right and left muscles diameters will be recorded with a 2-minute interval between trials.
Lumbar multifidus assessment will be performed at, the fifth lumbar vertebra, marking its spinal process. |
Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Muscle trunk flexor and extensor endurance | Muscle trunk flexor endurance test will be used to assess the endurance strength of abdominal muscles by isometric endurance of trunk flexors. Time (in seconds) is measured, and higher scores represent better performance.
Muscle trunk extensor endurance test will be used to assess the endurance strength of back extensor muscles by isometric endurance of trunk extensors.Time (in seconds) is measured, and higher scores represent better performance. |
Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Flexibility of the lumbar spine | Original Schöber test will be used to assess lumbar spine flexibility. The assessor will determine the location of the lumbosacral junction and marks it with a horizontal line. A second mark will be drown 10cm above the first line. The difference between the measurements in erect and flexion positions will be recorded. Higher differences represent better flexibility. | Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Body Balance | Total body balance will be assessed with the Flamingo test. In standing position without shoes, participants will be asked to stay on one leg. Assessor will record the number of trials needed to complete 30 seconds of this static position. The average of both legs will be used. Lower scores represent better performance | Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Functional capacity | It will be assessed with theThe 6-min walk test (6MWT) to determine the maximum distance that each patient is able to walk within 6 min (in metres). Patients are instructed to walk as far as they can in 6 min, without stopping and without running, but increasing and decreasing the speed voluntarily. Higher scores represent better performance | Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Chronic fatigue | Muscular fatigue will be assessed with the Piper Fatigue Scale-Revised (PFS-R), originally developed to assess cancer-related fatigue, but also used to assess fatigue in other musculoskeletal disorders such as heart failure. It contains 22 items scoring from 0 to 10. Total score is average score of these 22 items (0-10). Lower scores reflect better performance. PFS-R has high reliability (Cronbach's a=0.96). | Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Body mass index | Height (in centimeters) and weight (in kilograms) will be assessed and then combined to report body mass index (BMI) in kg/m^2. | Baseline | |
Secondary | Skeletal muscle mass | Skeletal muscle mass (in kilograms) will be recorded with an impedance meter | Baseline | |
Secondary | Body fat | Body fat (in percentage) will be recorded with an impedance meter | Baseline | |
Secondary | Sexual function | It will be assessed with the Female Sexual Function Index questionnaire (FSFI) (19 item) divided in 6 domains:desire, arousal, lubrication, orgasm, satisfaction and pain.
Items are answered on a 6-point Likert-type scale (with the exception of items 1 and 2, answered on a 5-point Likert-type scale). Scores of individual items from each domain are summed and multiplied by the domain factor. The global score is obtained by the sum of all domain scores, ranging from 2 to 36. Higher values correspond to better sexual function |
Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Gastrointestinal function | It will be assessed with the Gastrointestinal Quality of Life Index (GLQI) (36 items) grouped in 5 domains: digestive symptoms, physical status, emotions, social dysfunction and effects of medical treatment. Each item is scored from 0 (worst appreciation) to 4 (best appreciation). Scores of items are summed to obtain the global score, which ranges from 0 (worst) to 144 (best quality of life). | Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Sleep quality | It will be assessed with the Pittsburgh Sleep Quality Index (PSQI) (19 items), grouped in seven "components": subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component ranges from 0 (lowest dysfunction) to 3 (greatest dysfunction), and the PSQI global score is obtained by the sum of component's scores, and thus, ranges from 0 to 21, with higher scores indicating poor sleep quality. | Baseline, inmediately after intervention and 1-year post-intervention | |
Secondary | Self-perceived physical fitness | Regular physical activity will be estimated through the Minnesota Leisure Time Physical Activity Questionnaire (MLTPAQ), that has shown a moderate reliability to indirectly estimate physical activity (Spearman rank correlation coefficient > 0.69). During an interview, the assessor will ask each women the number of days per week and the amount of time (in minutes) per day that they spent doing each of the 63 activities listed in the questionnaire. Finally, an activity metabolic index is calculated by multiplying the number of days per week, the amount of time per day and the standard intensity codes assigned to each activity. This score approximates Kcal/day of energy expenditure. | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01931670 -
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
|
Phase 3 | |
Recruiting |
NCT05648669 -
A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain
|
Phase 3 | |
Completed |
NCT04081532 -
The Effectiveness of Laparoscopic Treatment of Superficial Endometriosis for Managing Chronic Pelvic Pain
|
N/A | |
Recruiting |
NCT06101303 -
Endometriosis Pain
|
||
Completed |
NCT04665414 -
Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI
|
||
Completed |
NCT03690765 -
Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis
|
||
Recruiting |
NCT05153512 -
ADOlescent DysmenoRrhea Endometriosis Assessment Magnetic Resonance Imaging (Adodream)
|
||
Active, not recruiting |
NCT04171297 -
Ultrasound Evaluation of the Pelvis in Women With Suspected Endometriosis Scheduled for Laparoscopic Surgery
|
||
Recruiting |
NCT04172272 -
The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures
|
N/A | |
Completed |
NCT04565470 -
Strategies of Self-management of Endometriosis Symptoms
|
||
Completed |
NCT03613298 -
Treatment by HIFU With Focal One® of Posterior Deep Infiltrating Endometriosis Lesions With Intestinal Involvement.
|
N/A | |
Withdrawn |
NCT05568940 -
Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids
|
||
Not yet recruiting |
NCT03464799 -
Does Immunotherapy Have a Role in the Management of Endometriosis?
|
||
Active, not recruiting |
NCT03002870 -
Characteristics of Patient Population With Endometriosis
|
N/A | |
Withdrawn |
NCT03272360 -
Endometriosis Biomarker Discovery Study
|
N/A | |
Completed |
NCT02973854 -
Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Endometriosis: Identification of Potential Relevant Biomarkers to Diagnose and Treat
|
||
Recruiting |
NCT02481739 -
Laparoscopic Surgical Management of Endometriosis on Fertility
|
N/A | |
Active, not recruiting |
NCT02754648 -
Three Different Laparoscopic Approaches for Ovarian Endometrioma and the Effect on Ovarian Reserve
|
N/A | |
Completed |
NCT06106932 -
GnRH-a on Angiogenesis of Endometriosis
|
N/A | |
Completed |
NCT02387931 -
Supplementation in Adolescent Girls With Endometriosis
|
Phase 4 |